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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effects of interventions to improve vaccine uptake among adolescents in low, middle and high-income countries.
B A C K G R O U N D
Vaccines are among the most successful and cost-effective pub-
lic health interventions available for preventing the morbidity
and mortality caused by vaccine-preventable diseases (Centers for
Disease Control and Prevention 2006). However, vaccine-pre-
ventable diseases remain a major cause of morbidity and mor-
tality among adolescents and young adults (Decade of Vaccines
Collaboration 2013). Vaccinating adolescent girls before the on-
set of sexual activity with vaccines against human papillomavirus
(HPV) can substantially reduce the risk of cervical cancer later in
life. Therefore, with most vaccines, the public health benefits of
vaccinating adolescents is mainly observed in early to late adult-
hood. Globally, cervical cancer is the fourth most frequent cancer
among women with an estimate of 530,000 new cases reported
in 2012 (World Health Organization 2015). Cervical cancer ac-
counted for 7.5% of all female cancer deaths globally in 2012
(World Health Organization 2015). Many vaccine-preventable
diseases and deaths among young adults are due to low vacci-
nation coverage among the adolescent group. In addition, there
are no adolescent vaccination policies in the majority of low- and
middle-income countries (LMICs) (Principi 2013; World Health
Organization 2015). There is therefore a need to conduct studies
that can inform public health policy-makers on better strategies
to increase vaccine uptake among adolescents.
Immunisation with an effective vaccine results in individuals ac-
quiring protective immunity against the targeted pathogen.When
sufficiently large number of individuals are vaccinated within a
population, herd immunity develops and this prevents the spread
of the targeted infectious disease within both vaccinated and
unvaccinated individuals (Lee 2005; Mackroth 2010; Zipursky
2010). Due to their immature immune systems, infants and
younger children are more vulnerable to infectious pathogens
than adults. Therefore, most vaccines are administered early in
life (Principi 2013; Rodewald 1998). However, immunity in-
duced by some vaccines, such as diphtheria, tetanus and pertussis,
wanes over time, leading to suboptimal immunity and less herd
immunity around the onset of adolescence (Decade of Vaccines
Collaboration 2013; Lee 2005; Mackroth 2010; Zipursky 2010).
It is therefore necessary to give booster vaccines during adolescence
to maintain protective immunity. In some settings, these booster
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vaccines are never administered to adolescents and young adults
(Principi 2013; World Health Organization 2015).
Vaccines given during adolescence include, among others, those
against HPV, tetanus, diphtheria and acellular pertussis (Tdap), as
well as meningococcal disease (Gilkey 2014; Harris 2009). Future
vaccines, such as those against human immunodeficiency virus
(HIV) and Mycobacterium tuberculosis (M.tb), are likely to target
adolescents as the primary population (Gowda 2012; Zipursky
2010). Extending vaccination throughout the life course, includ-
ing adolescence, is a strategy advocated by the Global Vaccine Ac-
tion Plan (GVAP) 2011-2020 (Decade of Vaccines Collaboration
2013). The rationale for the strategy of reaching individuals
throughout life is to achieve the highest reduction in the incidence
of vaccine-preventable diseases. Therefore, it is crucial to achieve
optimal adolescent vaccination uptake (Clements 2004;Mackroth
2010; Zipursky 2010). We propose that studies that can inform
health policy-makers on potential approaches to improving the
uptake of vaccines among adolescents are urgently needed. This
is particularly so in sub-Saharan Africa where there are few estab-
lished national programmes for vaccinating adolescents.
The World Health Organization (WHO) defines adolescents as
persons aged between 10 and 19 years (WHO; WHO 2009).
Targeting adolescents with relevant vaccines offers three bene-
fits: catch-up on missed vaccinations, boosting of waning im-
munity and primary immunisation with new vaccines (Brabin
2008; Mackroth 2010). The WHO recommends vaccinating
11- or 12-year olds against Neisseria meningitidis, Bordetella per-
tussis and HPV (World Health Organization 2014). Addition-
ally,WHO guidelines recommend vaccinating adolescents against
measles, mumps, rubella, varicella, hepatitis B and polio if they
have not previously been vaccinated as a catch-up strategy (Lee
2005; Society for Adolescent Health & Medicine 2013; World
Health Organization 2014). Despite these recommendations,
most LMICs are yet to implement adolescent-focused vaccination
policies (Shapiro 2007).
Optimal vaccination coverage rates among adolescents would re-
sult in reduced morbidity and mortality associated with vaccine-
preventable diseases, as well as reduced disease spread to children
and the elderly (Lee 2005; Principi 2013; Zipursky 2010). The
2014 global statistics show that 25% of the world population (1.8
billion) consists of young people aged 10 to 24 years (Population
Reference Bureau 2013), suggesting that optimal vaccination cov-
erage among the large number of young persons would achieve
enormous public health benefits, which include reduced disease
transmission through herd immunity and a healthier population
(Mackroth 2010; Zipursky 2010). A logical strategy for improv-
ing vaccine uptake is the introduction of national routine ado-
lescent immunisation programmes in LMICs. This strategy has
been proposed by the GVAP 2011-2020 (Decade of Vaccines
Collaboration 2013). TheDecade of VaccinesCollaboration states
that “the benefits of immunisation should be more equitably ex-
tended to all children, adolescents and adults” (Decade of Vaccines
Collaboration 2013). Some high-income countries have reported
high vaccine uptake among adolescents (Principi 2013). In most
LMICs, especially in sub-Saharan Africa, routine adolescent vac-
cination programmes do not exist (Shapiro 2007). In all settings,
effective interventions are needed to increase and sustain high and
equitable uptake of vaccines among adolescents. Our review will
establish the strategies associated with high vaccine uptake in all
settings and assess the applicability of these strategies in LMICs.
Description of the condition
Adolescent vaccination delivery strategy
Most countries lack specific healthcare programmes for adoles-
cents, leading to less contact between adolescents and the health-
care system (Mackroth 2010; Principi 2013; Wiysonge 2012a;
Wiysonge 2012b). In many settings, adolescents usually turn to
physicians only when they are ill and so there are limited oppor-
tunities to inform them that vaccines are important and should be
administered (Cawley 2010; Principi 2013). Healthcare provider
advice that a vaccine is best administered as soon as possible in
a vaccination centre only works for infants and children but not
for adolescents (Principi 2013). Adolescents are more interested
in their current health condition than possible future vaccine-
preventable diseases (Principi 2013). Schools have been used ex-
tensively as a delivery platform for vaccinating large numbers of
school-aged children (Barry 2013; Cawley 2010; Harris 2009;
Principi 2013; Robbins 2011; Tsu 2009). However, school-based
vaccination programmes may not be entirely successful in coun-
tries with suboptimal school attendance rates (Mackroth 2010;
Warren 2004; Watson-Jones 2012; Zipursky 2010). School atten-
dance rates in some LMICs are variable and often poor due to fac-
tors such as geographical location, socio-economic status and gen-
der (Mackroth 2010;Warren 2004;Watson-Jones 2012; Zipursky
2010). Strategies such as mass immunisation campaigns can be
used to complement school-based vaccination programmes in set-
tings with poor school attendance rates (Clements 2004).
Common barriers to adolescent vaccination
The most common barriers to vaccination include lack of knowl-
edge about vaccines and vaccine-preventable diseases, negative at-
titudes towards vaccination fromadolescents, parents, teachers and
healthcare providers, poor vaccine infrastructure programmes and
financial constraints (Gowda 2012; Machingaidze 2013; Society
for Adolescent Health & Medicine 2013).
Lack of knowledge about vaccines and vaccine-preventable dis-
eases in key role-players, such as parents, teachers, adolescents and
healthcare providers, is amajor challenge that hinders optimal vac-
cine uptake by adolescents (Brabin 2008; Cawley 2010; Gowda
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2012; Harris 2009; Mahomed 2008; Society for Adolescent
Health & Medicine 2013; Wiysonge 2012a). Parents (defined as
one who nurtures and raises a child or a relative who plays the
role of guardian) (Oxford Dictionaries a) are routinely involved in
the decision-making process about vaccine administration to their
children. Teachers (defined as a professional person who teaches
or instructs) (Oxford Dictionaries b) can play a crucial role in
adolescent vaccination uptake since school-based vaccination pro-
grammes, where they exist, are a popular platform for vaccination
of adolescents (Barry 2013; Tsu 2009).
Healthcare providers give advice to parents and adolescents on
vaccination. The ability of healthcare providers to keep up-to-date
with knowledge on vaccines is essential, particularly when new
vaccines are recommended (Gowda 2012; Principi 2013). Health-
care providers should continuously read the latest editions of the
WHO adolescent vaccine guidelines to improve their knowledge
of vaccines (World Health Organization 2014). Careful and fac-
tual advice on vaccination to adolescents and their guardians by
healthcare providers will result in more willingness to get vacci-
nated.
In some situations, the final decision on whether an adolescent
will be vaccinated or not may be entirely dependent on the par-
ents. For example, adolescents, and in particular those at an earlier
age (10 to 13 years old) (WHO; WHO 2009), may not have an
independent final decision on whether to get vaccinated (Barry
2013; Principi 2013). Therefore, educating adolescents about vac-
cination may have long-term positive benefits on vaccine uptake
among this age group (Barry 2013; Principi 2013). It is likely that
more vaccine-informed adolescents may be more able than less
informed peers to positively guide and influence their parents and
peers on vaccinations. In addition, adolescents are future parents
and investing resources in educating adolescents about vaccination
will likely lead to improved uptake of vaccines by their children
(Barry 2013). Hence, adequate knowledge and positive attitudes
towards vaccination among parents, teachers and adolescents may
improve the uptake of vaccines among adolescents (Gowda 2012;
Mahomed 2008).
Another factor that may influence vaccine uptake among adoles-
cents is vaccine safety. Adolescents’ fear of adverse events following
vaccination may lead to less interest in getting vaccinated, result-
ing in reduced vaccination coverage (Principi 2013).
The high cost of new vaccines and the unavailability of vaccines
are known barriers to achieving high vaccination coverage among
adolescents in LMICs (Perlman 2014; Principi 2013). For exam-
ple, although the high cost of HPV vaccines (two doses are re-
quired) precludes access, continued price reduction for HPV will
allow governments in LMICs to provide the vaccine to the target
population (Kaddar 2013; Perlman 2014). In Africa, several coun-
tries, namely Rwanda,Uganda, Cameroon, Tanzania, Lesotho and
South Africa, have introduced HPV vaccination to prevent cervi-
cal cancer through school-based programmes (Perlman 2014).
Description of the intervention
Interventions to enhance the uptake of vaccines by adolescents
may be multi-pronged:
Adolescents and their communities-oriented
interventions
• Interventions to ’inform’ or ’educate’ enable adolescents
and their communities to understand the meaning and relevance
of vaccination (Willis 2013). Such interventions may be
delivered face-to-face or via written mail, telephone
conversation, audio visual presentation or drama, printed
materials, websites, multi-media campaigns or community
events (Willis 2013). These types of interventions may be
directed at individuals, groups and providers and may include
information about vaccine-preventable diseases; the risks and
benefits of vaccines; where, how and when to access vaccine
services; and who should be vaccinated (Oyo-Ita 2014; Williams
2011; Willis 2013). Adolescents and communities may receive
education about vaccines through prominently displayed posters
in waiting rooms, brochures, e-mails and website resources
(Stinchfield 2008).
• Client reminder/recall interventions involve reminding
members of a target population that vaccinations are due
(reminders) or late (recall). Reminders and recalls are delivered
using various methods, such as telephone calls, letters or
postcards (Briss 2000; Oyo-Ita 2014; Stinchfield 2008; Task
Force on Community Preventive Services 2000; Williams 2011;
Willis 2013). The contents of reminder/recalls may include
personalised information related to a specific upcoming or
missed appointment, or may be more focused on promoting
general awareness of available vaccines (Stinchfield 2008; Willis
2013). We will not include adolescent reminder/recall of
immunisation services in this review, as there is already a
Cochrane review on this intervention (Jacobson 2005).
• Adolescent or community incentives involve providing
financial or other incentives to motivate people to accept
vaccinations (Briss 2000; Oyo-Ita 2014; Task Force on
Community Preventive Services 2000). Incentives can be rewards
or gifts (Task Force on Community Preventive Services 2000).
Legislative interventions
• This involves a proof of vaccination record during school or
college entrance. These are laws or policies that require students
to show proof of immunisation records prior to school admission;
failure to do this denies admission (Briss 2000; Oyo-Ita 2014;
Task Force on Community Preventive Services 2000).
Provider-oriented interventions
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• Provider reminder/recall interventions inform vaccinators
that individual clients are due (reminder) or overdue (recall)
vaccinations. Reminders may be delivered through client charts,
computer or postal/electronic mail among many others (Briss
2000; Oyo-Ita 2014; Task Force on Community Preventive
Services 2000; Ward 2012; Williams 2011). We will not include
provider reminder/recall of immunisation services, as there is
already a Cochrane review on this intervention (Jacobson 2005).
• Audit and feedback for vaccinators involves retrospectively
evaluating the performance of the vaccinators in administering
vaccines and providing feedback to them (Briss 2000; Oyo-Ita
2014; Stinchfield 2008; Task Force on Community Preventive
Services 2000; Williams 2011). This information is given to
providers to motivate them to improve immunisation services.
• Provider education involves giving information regarding
vaccinations to providers to increase their knowledge and to
encourage them to adopt positive attitudes towards vaccination.
Techniques by which information is delivered can include
written materials, videos, lectures, continuing medical education
programmes and computerised software (Briss 2000; Stinchfield
2008; Task Force on Community Preventive Services 2000;
Ward 2012; Williams 2011).
Health system interventions
• Outreach programmes include school-based immunisation
and mass campaigns. School-based immunisation outreach is
intended to improve delivery of vaccinations to school-going
children aged between five and 18 years (Task Force on
Community Preventive Services 2000). School-based
interventions usually include vaccination-related education of
students about either provision of vaccinations or referral for
vaccinations (Briss 2000; Oyo-Ita 2014; Task Force on
Community Preventive Services 2000). Mass campaign outreach
programmes target adolescents both in school and out of school.
For the age group that is out of school, mass campaign outreach
programmes can be used to complement school-based
vaccination programmes in settings with poor school attendance
rates (Clements 2004).
• Expanding access in healthcare settings to increase the
availability of vaccines in the medical or public health clinical
settings in which vaccinations are offered. This can be achieved
using several methods such as: reducing the distance from the
setting to the population; increasing or changing the hours
during which vaccination services are provided; delivering
vaccinations in clinical settings in which they were previously not
provided (e.g. emergency departments, inpatient units or
subspecialty clinics); or reducing administrative barriers to
obtaining vaccination services within clinics (e.g. developing a
’drop-in’ clinic or an ’express lane’ vaccination service) (Briss
2000;Stinchfield 2008; Task Force on Community Preventive
Services 2000).
• Reducing out-of-pocket costs. This can be implemented by
subsiding the costs of vaccines, paying for vaccinations,
providing insurance coverage or reducing co-payments for
vaccinations at the point of service (Briss 2000; Oyo-Ita 2014;
Task Force on Community Preventive Services 2000).
Multicomponent interventions
Multicomponent interventions are approaches that include more
than one intervention, with the aim of addressing a variety of bar-
riers and health concerns in relation to adolescents vaccine up-
take. Such interventions would enable communities to be aware
of the immunisation services available to them, demonstrate the
utility and relevance of these services, provide community mem-
bers with the knowledge and information base to effectively take
advantage of the services, and to also incorporate a variety of asso-
ciated provider or health system strategies to improve immunisa-
tion rates (Briss 2000; Oyo-Ita 2014; Task Force on Community
Preventive Services 2000).
How the intervention might work
A logic model of interventions used to increase adolescent vacci-
nation and the associated health outcomes is shown in Figure 1.
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Figure 1. Logic framework on interventions for improving uptake of adolescent vaccines
No logic model or conceptual framework has been described that
shows an integrated perspective on interventions to increase vacci-
nation among adolescents. The evidence-based conceptual model
of factors that influence HPV vaccination among adolescent girls
has, however, been described (Fernández 2010). This model sug-
gested a useful framework for examining the impact of personal,
interpersonal, organisational and broader community as well as
societal factors on vaccination (Fernández 2010). Our logic model
proposes that such factors, alone or in combination, will have an
influence on adolescent vaccination.
Interventions improve vaccine uptake among adolescents through
the following:
• Increasing demand for immunisation services by
adolescents, for example:
◦ interventions to inform or educate adolescents and/or
their parents;
◦ interventions to remind or recall adolescents and/or
their parents;
◦ financial and non-financial incentives for adolescents
and/or their parents; and
◦ vaccination requirement for high school or university
attendance.
• Enhancing access to immunisation services through
provider-oriented interventions, such as:
◦ education, audit and feedback to healthcare workers;
◦ reminders and recall for healthcare workers; and
◦ supportive supervision of healthcare workers.
• Enhancing access to immunisation services through health
system-oriented interventions, such as:
◦ reliable cold chain systems;
◦ improved vaccine stock management;
◦ regular outreach sessions, i.e. school based
programmes and mass campaign programmes;
◦ expansion of vaccine services; and
◦ integration of immunisation with other health services.
• Increasing both demand for and access to immunisation
services, for example multicomponent interventions.
Why it is important to do this review
There is a knowledge gap around interventions to improve vac-
cine uptake among adolescents, especially in LMICs. Adoles-
cents represent 25% of the global population. High-income coun-
tries (HICs) have reported high adolescent vaccine uptake, yet
in LMICs there are no existing programmes for routine vaccina-
tion of adolescents. Our review proposes to evaluate the evidence
on the strategies that can be adopted to improve vaccine uptake
among adolescents and to assess the applicability of these strate-
gies in LMICs. Such strategies will not only improve the uptake of
current vaccines among adolescents, but are also likely to increase
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the uptake of future vaccines against tuberculosis (TB) and HIV.
In addition, this review will be used to formulate new policies on
the vaccination of adolescents where none exist and to advocate for
strengthening existing adolescence vaccination policies.We are not
aware of any previous systematic review that has assessed interven-
tions to improve adolescent immunisation. However, a number
of reviews have assessed various strategies to improve immunisa-
tion coverage in children or the whole population (Jacobson 2005;
Kaufman 2013; Oyo-Ita 2014; Saeterdal 2012; Williams 2011;
Willis 2013). One review assessed the reminder/recall interven-
tion in a whole population. This review only found one study on a
reminder and recall intervention in adolescents (Jacobson 2005).
The authors found that an autodialer intervention was not suc-
cessful in significantly increasing immunisations (Jacobson 2005).
In the other reviews, concepts such as vaccination strategy inter-
ventions and barriers to immunisation have been well described
(Jacobson 2005; Kaufman 2013; Oyo-Ita 2014; Saeterdal 2012;
Williams 2011; Willis 2013). In our review, we will use a similar
approach among the adolescent population.
O B J E C T I V E S
To evaluate the effects of interventions to improve vaccine uptake
among adolescents in low, middle and high-income countries.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider the following study designs: randomised con-
trolled trials (RCTs), non-randomised controlled trials (non-
RCTs), interrupted time series designs (ITS) and controlled be-
fore-after studies (CBAs), which meet the quality criteria used by
theCochrane Effective Practice andOrganisation of Care (EPOC)
Group (EPOC 2015a). We will include both individually ran-
domised and cluster-randomised controlled trials. For cluster-
RCTs, we will only include those with at least two intervention
and two control clusters. Following the EPOC Group criteria, we
will include an ITS study only if outcomes are measured during
at least three points before and three points after the intervention,
and we will exclude simple pre-post designs. For a CBA study to
be included in the review, it must include at least two intervention
groups and at least two comparable control groups, with simulta-
neous data collection.
We will exclude CBA studies and non-RCTs that have only two
study locations, in accordance with the EPOC Group criteria for
inclusion of studies in systematic reviews of effects (EPOC 2015a).
Types of participants
Adolescents (defined as individuals aged 10 to 19 years) eligible
for WHO-recommended vaccines and their parents or healthcare
providers.
In the case of studies with interventions directed at mixed popu-
lations of children and adolescents, or adolescents and adults, we
will exclude a study if specific data for adolescents are not reported.
Types of interventions
Intervention
• Adolescents and their communities-oriented interventions,
for example:
◦ interventions to communicate with adolescents and/or
their caregivers about adolescent immunisation;
◦ financial and non-financial incentives for adolescents
and/or their caregivers.
• Legislative interventions:
◦ vaccination requirement for high school and university
attendance.
• Provider-oriented interventions, for example:
◦ any intervention to reduce missed opportunity (e.g.
audit and feedback, provider reminders); and
◦ health education, training and supportive supervision.
• Health system interventions, for example:
◦ interventions to improve the quality of services, such
as provision of reliable cold chain systems, provision of transport
for vaccination, vaccine stock management;
◦ outreach programmes, e.g. school-based immunisation
outreach and mass campaign outreach for age groups that will be
out of school;
◦ expanded services, e.g. extended hours for
immunisation services;
◦ increased immunisation budget;
◦ integration of immunisation services with other
services.
• Other interventions intended to improve adolescent
immunisation coverage, including multi-component
interventions.
Exclusions
We do not plan to include interventions to remind or recall recip-
ients or providers of immunisation services, as there is already a
Cochrane review on this topic (Jacobson 2005).
Equity considerations
The listed interventions are likely to have less or no impact on ado-
lescents who are not attending formal schooling (Mackroth 2010;
6Improving vaccination uptake among adolescents (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Warren 2004;Watson-Jones 2012; Zipursky 2010). Therefore, we
propose to assess other interventions aimed at non-school attend-
ing adolescents, such as mass campaign programmes (Clements
2004). For studies addressing school-based interventions or mass
campaign interventions, we will conduct a subgroup analysis if
sufficient data are available.
Comparisons
• Standard immunisation practices in the study setting.
• Alternative interventions.
• Similar interventions implemented with different degrees of
intensity.
Types of outcome measures
Primary outcomes
• Vaccination coverage (the proportion of adolescents who
have received the recommended dose of the vaccine in a study).
Secondary outcomes
• Cost of the intervention.
• Knowledge, attitudes and beliefs.
• Adverse events following immunisation.
• Adverse effects of the intervention.
• Incidence of vaccine-preventable diseases.
• Proportion of adolescents completing the schedule.
We will include studies that meet the inclusion criteria but do not
report the outcomes needed for this review and describe them in
the table of ’Characteristics of included studies’.
Search methods for identification of studies
We will develop comprehensive and highly sensitive search strate-
gies, with the assistance of the Cochrane EPOC Group Trials
Search Co-ordinator, for both published and unpublished arti-
cles, with no restrictions on language or publication date. The
search strategies for the electronic databases will incorporate the
Cochrane EPOC Group search strategy for RCTs, non-RCTs,
CBAs and ITS studies (EPOC 2015a), combined with selected
MeSH and free-text terms relating to adolescent vaccination up-
take literature globally.
Electronic searches
We will search the following databases for primary studies up to
21. Sept. 2015:
• Cochrane Central Register of Controlled Trials
(CENTRAL) 2015, part of The Cochrane Library (
www.thecochranelibrary.com);
• MEDLINE, Ovid;
• PubMed, NLM (for studies not in MEDLINE);
• EMBASE, Ovid;
• CINAHL, EBSCOhost;
• Africa-Wide Information, EBSCOhost;
• Global Health, Cab Direct;
• Scopus;
• Science Citation Index and Social Sciences Citation Index,
ISI Web of Knowledge (for papers citing any of the included
studies in the review).
We will search the following databases for related reviews:
• Cochrane Database of Systematic Reviews (CDSR) 2015,
part of The Cochrane Library (www.thecochranelibrary.com);
• Database of Abstracts of Reviews of Effectiveness (DARE)
2015, part of The Cochrane Library (
www.thecochranelibrary.com);
• PDQ-Evidence.
See Appendix 1 for the MEDLINE search strategy.
Searching other resources
Grey literature
• World Health Organization (WHO) (http://
www.who.int/).
• Global Alliance for Vaccine and Immunisation (GAVI) (
http://www.gavialliance.org/).
• United Nations Children’s Funds (UNICEF) (http://
www.unicef.org/).
• PATH Vaccine Resources Library (http://www.path.org/).
• US Centers for Disease Control and Prevention (CDC) (
http://www.cdc.gov/).
• The communication initiative network (http://
www.comminit.com/), http://www.nyam.org/library, http://
www.opengrey.eu/, http://www.eldis.org/.
• Immunization basics (http://
www.immunizationbasics.jsi.com/Index.html).
Trial registries
• Word Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/
en/).
• ClinicalTrials.gov, US National Institutes of Health (NIH)
(http://clinicaltrials.gov/).
We will also search the reference lists of all eligible papers for
relevant studies.
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Data collection and analysis
Selection of studies
Two authors (LH and BK) will screen the titles and abstracts to
select potentially eligible studies. We will then obtain the full text
of potentially eligible studies and two independent authors will
conduct the final selection for inclusion in the review. We will
resolve any disagreements regarding the inclusion of studies by
discussion or by consulting a third author. We will use a PRISMA
flow chart to summarise the search and selection of studies for the
review. We will include a table of all included studies in the final
review and document the reasons for exclusion of studies.
Data extraction and management
Two authors will independently extract data from selected studies
using an adapted version of the Cochrane data extraction form.
Disagreements on study selection and data extraction will be re-
solved by consensus between the two review authors, failing which
a third author will arbitrate. Prior to use, we will pilot the data
extraction form on at least four studies identified randomly from
the list of included studies.
The data extraction form will include the following eligibility cri-
teria:
• Setting of the study (city and country).
• Type of study: individual RCT, cluster-RCT, non-RCT,
CBA and ITS studies.
• Type of participants: adolescents, caregivers, health
providers.
• Type of interventions: frequency, timing, delivery method,
venue of delivery, deliverer of adolescent and community health,
health system and multi-component interventions.
• Types of outcomes measured: vaccine coverage (i.e.
proportion of adolescents immunised in a population based on
the different interventions), knowledge, attitudes and beliefs,
cost of intervention, adverse effects of the intervention, adverse
events following immunisation, proportion of adolescents
completing schedule and incidence of vaccine-preventable
diseases. We will include studies that meet the inclusion criteria
but do not report the outcomes needed for this review and
describe them in the table of ’Characteristics of included studies’.
Assessment of risk of bias in included studies
We will apply the Cochrane EPOC Group ’Risk of bias’ crite-
ria (EPOC 2015b) for randomised controlled trials (RCTs), non-
randomised controlled trials (non-RCTs), controlled before-after
studies (CBA) and interrupted time series (ITS) studies to deter-
mine the risk of bias of all eligible studies. For each included study,
we will report our assessment of risk of bias, i.e. low, high or un-
clear risk for each domain, together with a descriptive summary of
the information that influenced our judgement. Two review au-
thors will apply the criteria and we will discuss any disagreements
with a third review author.
Measures of treatment effect
We will express the result of each study as a risk ratio with its cor-
responding 95% confidence interval (CI) for dichotomous data,
or a mean difference with its 95% CI for continuous data. We
will group studies with broadly similar types of participants, in-
terventions, study designs and outcomes to get feasible results for
an overall estimate of effect. We will analyse ITS studies using a
regression analysis with time trends before and after the interven-
tions. We will present the results for the outcomes as change in
level and slope (Ramsay 2003).
Unit of analysis issues
If investigators report cluster-randomised trial data as if the ran-
domisation was performed on the individuals rather than the clus-
ters, we will request the intra-cluster correlation coefficient (ICC)
from the study authors; failing this we will obtain external es-
timates of the ICC from similar studies or available resources
(Campbell 2000). Once established, we will use the ICC to re-
analyse the trial data to obtain approximate correct analyses. We
will adjust the data by inflating the standard errors, i.e. multiplying
them by the square root of the design effect (Higgins 2011). We
plan to report the effect estimates and the corrected standard errors
from cluster-randomised trials with those from parallel-group de-
sign trials, noting that the analysis of data from that specific study
suffers from unit of analysis error (Higgins 2011). If insufficient
information is available to control for clustering in this way, we
will enter data into RevMan using individuals as the unit of analy-
sis. We will then perform sensitivity analyses to assess the potential
bias that may have occurred as a result of the inadequately con-
trolled clustered trials. We will also perform sensitivity analyses if
we obtained the ICCs from external sources, to assess the poten-
tial biasing effects of inadequately controlled cluster-randomised
trials (Donner 2001).
Dealing with missing data
Where necessary, we will contact the corresponding authors of
included studies to supply any unreported data. We will describe
missing data and dropouts for each included study in a ’Risk of
bias’ table, and discuss the extent to which the missing data could
alter our results. For CBA studies where relative measures are not
available, we will estimate the difference between outcome mea-
sures at two time points for both baseline and after the interven-
tion and then compare the difference between the groups. On the
other hand, if ITS studies are incorrectly analysed by the authors
and provide the data points, we will re-analyse ITS studies using
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a regression analysis with time trends before and after the inter-
vention, which adjust for autocorrelation and any periodic change
(Ramsay 2003).
Assessment of heterogeneity
We anticipate substantial variation in study results due to differ-
ences in the type of intervention, the type of setting, study de-
sign and risk of bias. We will describe in detail the anticipated
variation to be assessed based on clinical/contextual heterogene-
ity, i.e. the facility at which vaccination was provided (school or
healthcare centre), high- versus low-income countries, gender dif-
ferences, whether the recipients were healthy or not. School atten-
dance rates in some LMICs are variable and often poor therefore
we anticipate variation in equity with the type of intervention that
targets this group. On the other hand, knowledge of and attitudes
to adolescent vaccination are different between HIC and LMIC
vaccine recipients. We will examine statistical heterogeneity be-
tween study results using the Chi² test of homogeneity (with sig-
nificance defined at the alpha level of 10%). We will quantify any
statistical heterogeneity between study results using the I² statistic.
We will regard heterogeneity as substantial if the I² is greater than
30% (Higgins 2011).
Assessment of reporting biases
We will use a funnel plot to investigate the risk of publication bias
by intervention type, provided 10 or more studies are included
in the analysis for each intervention type. We will critically ex-
amine the funnel plot for asymmetry both visually and with the
use of formal tests. For continuous and dichotomous outcomes,
we will use the test proposed by Egger (Egger 1997) and the test
proposed by Harbord (Harbord 2006), respectively. In situations
where asymmetry is detected by either test or by visual assessment,
we will perform further exploratory analyses to investigate it. This
will include reviewing the included studies for small sample size
studies and their intervention effect.
Data synthesis
We will pool data from studies of similar interventions, similar
participants, similar outcomes and similar study designs in a meta-
analysis using the random-effects model if there is no significant
statistical heterogeneity, methodological difference or high risk of
bias. If we encounter variation between studies in the reported in-
terventions, participants, study designs and outcomemeasures, we
will not pool the results but summarise the findings in a narrative
format. We will report ITS studies as changes in level and slope.
If ITS studies are incorrectly analysed by the authors and provide
the data points, we will re-analyse them using a regression analysis
with time trends before and after the intervention, which adjust
for autocorrelation and any periodic change. Overall, we will in-
terpret the study findings by taking into account the methodolog-
ical quality of the studies and the strength of evidence. For each
observed effect, we will explicitly state the strength of evidence
and draw conclusions.
’Summary of Findings’ table and assessing the of
certainty of evidence
We will use the GRADE approach to assess the certainty of evi-
dence at outcome level (Guyatt 2008). We will set out the main
findings of the assessment across studies in ’Summary of find-
ings’ tables prepared using GRADE profiler software (GRADEpro
GDT).Wewill include the following outcomes in the Summary of
Findings table: vaccination coverage, cost of intervention, knowl-
edge, attitudes and beliefs, adverse events following immunisa-
tion, adverse effects of the intervention, incidence of vaccine-pre-
ventable diseases and proportion of adolescents completing the
schedule.
The GRADE approach results in an assessment of the certainty
of a body of evidence as high, moderate, low or very low (Guyatt
2008). High certainty evidence implies that “further research is
very unlikely to change our confidence in the estimate of effect”.
Moderate certainty evidence means that “further research is likely
to have an important impact on our confidence in the estimate of
effect andmay change the estimate”. Evidence is considered of low
certainty if “further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate”, and very low certainty if “we have very little
confidence in the effect estimate” (Balshem 2011).
Subgroup analysis and investigation of heterogeneity
Where sufficient data are available, wewill conduct subgroup anal-
yses, which will explore the effects of: vaccine given including fre-
quency of the vaccine; availability of a policy on adolescent vac-
cination including vaccination schedule; equity (school-based in-
terventions or mass campaign programmes); and country income
status (World Bank classification as either HICs or LMICs). We
will use the Chi² test for subgroup differences to test for subgroup
interactions.
Sensitivity analysis
Where sufficient data are available, wewill conduct, if applicable, a
sensitivity analysis to establishwhether themeta-analysis results for
the treatment effect are influenced by study designs and overall risk
of bias. We will perform sensitivity analyses by excluding studies
with a particular study design and studies with high risk of bias.
A C K N OW L E D G E M E N T S
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Appendix 1. MEDLINE search strategy
Medline, Ovid
# Searches Results
1 (vaccin* and (uptake or coverage)).ti. 2155
2 (vaccin* adj (uptake or coverage)).ab. 5760
3 or/1-2 6632
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(Continued)
4 Immunization/ 43773
5 Immunization Schedule/ 9277
6 Immunization, Secondary/ 7181
7 Immunization Programs/ 8257
8 Immunotherapy, Active/ 2298
9 Vaccination/ 59448
10 Mass Vaccination/ 2324
11 or/4-10 120620
12 Diphtheria/ 5821
13 Tetanus/ 8732
14 Bordetella Infections/ 889
15 Bordetella Pertussis/ 4661
16 Whooping Cough/ 7213
17 Measles/ 12252
18 Mumps/ 3918
19 Rubella/ 7497
20 Poliomyelitis/ 16087
21 Poliomyelitis, Bulbar/ 616
22 Tuberculosis/ 58190
23 Tuberculosis, Pulmonary/ 68710
24 Mycobacterium Tuberculosis/ 40363
25 Hepatitis A/ 18147
26 Hepatitis A virus/ 903
27 Hepatitis A Virus, Human/ 511
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(Continued)
28 Hepatitis B/ 38784
29 Hepatitis B, Chronic/ 11087
30 Hepatitis B virus/ 21651
31 Chickenpox/ 6891
32 Papillomavirus Infections/ 18094
33 Herpesviridae Infections/ 13314
34 Herpes Simplex/ 13129
35 Herpes Genitalis/ 4344
36 Herpes Labialis/ 1140
37 Herpes Zoster/ 8959
38 Meningococcal Infections/ 5498
39 Meningitis, Meningococcal/ 4839
40 Neisseria meningitidis/ 7423
41 exp HIV Infections/ 247938
42 HIV/ 17360
43 HIV-1/ 70967
44 HIV-2/ 3965
45 Neoplasms/ 324983
46 or/12-45 930573
47 11 and 46 28632
48 Diphtheria-Tetanus-Acellular Pertussis Vaccines/ 802
49 Diphtheria-Tetanus-Pertussis Vaccine/ 2524
50 Diphtheria-Tetanus Vaccine/ 327
51 Pertussis Vaccine/ 4706
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(Continued)
52 Vaccines, Combined/ 2049
53 Diphtheria Toxoid/ 2870
54 Tetanus Toxoid/ 6660
55 Measles-Mumps-Rubella Vaccine/ 2321
56 Measles Vaccine/ 6228
57 Mumps Vaccine/ 1632
58 Rubella Vaccine/ 2972
59 Poliovirus Vaccines/ 1172
60 Poliovirus Vaccine, Oral/ 3691
61 Poliovirus Vaccine, Inactivated/ 2562
62 Tuberculosis Vaccines/ 1306
63 BCG Vaccine/ 17353
64 Viral Hepatitis Vaccines/ 3419
65 Hepatitis A Vaccines/ 1484
66 Hepatitis B Vaccines/ 8128
67 Chickenpox Vaccine/ 1717
68 Papillomavirus Vaccines/ 4923
69 Meningococcal Vaccines/ 2612
70 AIDS Vaccines/ 7238
71 or/48-70 73086
72 ((diphtheria? or tetanus or bordetella or pertussis or whooping
cough or measles or mumps or rubella? or rubeola or mmr or
polio* or infantile paralysis or tuberculosis or tuberculoses or
bcg or calmette* or hepatitis or chickenpoxor varicella or papil-
loma* or herpes or meningococcal or meningitidis or meningi-
tis or acquired immunodeficiency syndrome or aids or human
immunodeficiency virus or hiv? or cancer? or neoplasm?) adj3
(vaccin* or revaccinat* or immunization or immunisation or
73091
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(Continued)
immunotherapy)).ti,ab
73 ((tripe or combin*) adj vaccin*).ti,ab. 1743
74 or/72-73 74012
75 3 or 47 or 71 or 74 117319
76 Adolescent/ 1708075
77 Adolescent Health Services/ 4723
78 (adolescent? or youth? or young adult? or teenager? or teen? or
juvenile?).ti,ab
324075
79 or/76-78 1836581
80 75 and 79 19423
81 randomized controlled trial.pt. 411691
82 controlled clinical trial.pt. 91681
83 multicenter study.pt. 196215
84 pragmatic clinical trial.pt. 210
85 non-randomized controlled trials as topic/ 28
86 interrupted time series analysis/ 78
87 controlled before-after studies/ 59
88 (randomis* or randomiz* or randomly).ti,ab. 634375
89 groups.ab. 1505036
90 (trial or intervention? or effect? or impact? or multicenter or
multi center or multicentre or multi centre).ti
1833915
91 (controlled or control group? or (before adj5 after) or (pre
adj5 post) or ((pretest or pre test) and (posttest or post test))
or quasiexperiment* or quasi experiment* or evaluat* or time
series or time point? or repeated measur*).ti,ab
3393251
92 or/81-91 5837461
93 exp Animals/ 18518807
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(Continued)
94 Humans/ 14399247
95 93 not (93 and 94) 4119560
96 review.pt. 2052355
97 meta analysis.pt. 60297
98 news.pt. 177550
99 comment.pt. 669752
100 editorial.pt. 396325
101 cochrane database of systematic reviews.jn. 11883
102 comment on.cm. 669752
103 (systematic review or literature review).ti. 66358
104 or/95-103 7117780
105 92 not 104 4220689
106 80 and 105 6674
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